CTRI/2011/07/001903已完成1 期
A Randomized, Open Label, Active Controlled, Phase I Clinical Study to Assess the Safety and Immunogenicity of SIIL?s Purified Vero Cell Rabies Vaccine (PVRV) in Healthy Adults as a Pre-Exposure Immunization.
Serum Institute of India Ltd0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Willing to give informed consent and whose clinical laboratory examinations are within the clinically acceptable normal range.
排除标准
- •1. Subjects participating in any other clinical trial, 2. previous history of Rabies. 3. received rabies immunoglobulin 4. febrile illness. 5. Known systemic hypersensitivity to vaccine components 6. pregnancy or positive urine pregnancy test. 7. Breast-feeding 8. thrombocytopenia 8. subject at high risk for rabies exposure during the trial period. 9. concomitant antimalarial drugs.
研究者
相似试验
已完成
2 期
A study of Purified Vero Rabies vaccine for prophylaxis in patients with rabies exposureCTRI/2012/11/003135Serum Institute of India Limited181
招募中
1 期
Setrusumab vs Bisphosphonates in Pediatric Subjects with Osteogenesis ImperfectaMedDRA version: 20.0Level: PTClassification code: 10031243Term: Osteogenesis imperfecta Class: 100000004850osteogenesis imperfectaCTIS2023-504196-24-00ltragenyx Pharmaceutical Inc.68
进行中（未招募）
1 期
An Investigational Immuno-therapy Study to Compare Relatlimab in Combination with Nivolumab with Various Standard-of-Care Therapies in Patients with Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) AdenocarcinomaMedDRA version: 20.1 Level: PT Classification code 10017758 Term: Gastric cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10056267 Term: Gastroesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001070-20-ESBristol-Myers Squibb International Corporation2,180
已完成
1 期
Phase I Clinical Trial of SII Yellow Fever VaccineCTRI/2020/09/027594Serum Institute of India Pvt Ltd60
进行中（未招募）
1 期
A study investigating the efficacy and safety of anetumab ravtansine as 2nd line treatment for malignant pleural mesothelioma.EUCTR2012-003650-88-FRBayer HealthCare AG183